Crispr Treatment for Duchenne Muscular Dystrophy, a Muscle Disease Considered Incurable

Considered one of the century’s most important discoveries, CRISPR-CAS9 technology continues breaking new ground in genetic disease treatment. In February 2018, Science published a study on Duchenne muscular dystrophy (Duchenne Muscular Dystrophy = DMD), a fatal muscle disease with no treatment, developing effective crispr therapy.
Duchenne muscular dystrophy involves muscle degeneration (breakdown/wasting) and weakness. Mutations in the Dystrophin gene cause this genetic disease. The gene’s product, dystrophin protein, keeps muscle cells together and healthy. In Duchenne muscular dystrophy, it cannot function, and muscles weaken. For diseases caused by specific gene mutations, gene editing treatments offer considerable hope.
- Related Topic: In 2017, 9 groundbreaking CRISPR developments
What is Duchenne muscular dystrophy?
This X-linked recessive muscle disease is inherited through carrier mothers, with sons affected. A carrier mother’s son has a 50% chance of being affected and a daughter a 50% chance of being a carrier. Symptoms appear by age 5: once walking begins, the child cannot walk quickly or well, tires easily and falls frequently. It occurs in one in every 3600 boys. Muscles weaken throughout the body, beginning in the legs and hips, eventually causing loss of mobility; involvement of heart muscle causes death.
The study obtained induced pluripotent stem cells from patients’ cells. These were then reprogrammed using Crispr technology into heart cells producing dystrophin. Researchers subsequently formed heart muscle tissue from these cells.
According to the study results:
Crispr-programmed heart muscle cells readily produced dystrophin and began contracting like normal heart muscle cells.
Analyses suggested effectiveness in 60% of patients. Treated mice and dogs had disease control lasting more than 1 year.
The video below shows heart muscle cells before and after CRISPR treatment
What does this study tell us?
- Crispr treatment offers great promise for genetic diseases. This study made important progress against otherwise untreatable muscle diseases.
- It is important to emphasize that studies remain at the laboratory stage. With these effective results, human clinical trials for inherited muscular dystrophies will begin soon.
Video: What is CRISPR-CAS9 genetic technology?
Sources
Correction of diverse muscular dystrophy mutations in human engineered heart muscle by single-site genome editing.
Science Advances, 2018.
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.